In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
university of oklahoma
Oblato acquires all rights to glioblastoma drug from OMRF
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
OMRF names new board member and VP
OMRF hosted its semiannual meeting on Thursday.
OMRF brain cancer drug enters clinical trials at OU cancer center
OMRF, Stephenson Cancer Center begin tests of experimental compound
At this moment, you probably think of yourself as an I. As in, “I’m going to the grocery store to get some bread.” Or, “I’m running a slight fever.” Maybe even, “I’m so excited to read this new issue of Findings!” But what if you’re using the wrong pronoun? What if, despite your conscious perception, […]